NCT04209114 trial: what clinicians have said so far
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
- NCT04209114 ↗
- Completed
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04209114 (bempegaldesleukin plus nivolumab; nivolumab in cisplatin-ineligible muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04209114 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Bladder Cancer; Bladder Tumor; Muscle-Invasive Bladder Cancer
- Interventions
- Nivolumab; Radical cystectomy (RC); Bempegaldesleukin
- Arms
- Arm A: Combination Therapy · Experimental
- Arm B: Monotherapy · Experimental
- Arm C: Standard-of-care · Other
- Enrollment
- 114
- Primary outcomes
- Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care
- Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care
- Sponsor
- Bristol-Myers Squibb with Nektar Therapeutics
- Start
- Feb 5, 2020
- Primary completion
- Jun 7, 2023
- Results posted
- Yes
- Registry record
- NCT04209114 · updated Jun 27, 2024